Cibus, Inc.
$1.56
▲
2.59%
2026-04-21 05:55:01
www.cibus.com
NCM: CBUS
Explore Cibus, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$118.83 M
Current Price
$1.56
52W High / Low
$4.19 / $1.09
Stock P/E
—
Book Value
$0.4
Dividend Yield
—
ROCE
-23.41%
ROE
-2.21%
Face Value
—
EPS
$-2.78
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
118
Beta
1.93
Debt / Equity
1,227.56
Current Ratio
0.72
Quick Ratio
0.72
Forward P/E
-7.55
Price / Sales
33.53
Enterprise Value
$362.53 M
EV / EBITDA
-5.89
EV / Revenue
99.62
Rating
Buy
Target Price
$14.67
EPS Forecast (FY)
—
Pros
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Lexeo Therapeutics, Inc. | $6.53 | — | $511.94 M | — | -85.23% | -55% | $10.99 / $2.19 | $3.38 |
| 2. | OnKure Therapeutics, Inc. | $4.99 | — | $68.37 M | — | -112.02% | -74.39% | $5.06 / $1.7 | $4.11 |
| 3. | Janux Therapeutics, Inc. | $15.87 | — | $962.36 M | — | -16.15% | -11.48% | $35.34 / $12.12 | $15.85 |
| 4. | Phathom Pharmaceuticals, Inc. | $13.47 | — | $1.04 B | — | -125.87% | 63.97% | $18.31 / $2.21 | $-6.13 |
| 5. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 6. | XOMA Royalty Corporation | $40 | 14.61 | $463.38 M | 1.18% | 4.79% | 34.12% | $40.74 / $20.59 | $7.07 |
| 7. | Compugen Ltd. | $2.88 | 7.61 | $269 M | — | 23.38% | 44.84% | $2.94 / $1.23 | $1.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 1.06 M | 0.61 M | 0.93 M | 1.03 M | 1.21 M |
| Operating Profit | -13.46 M | -15.44 M | -17.95 M | -20.62 M | -18.02 M |
| Net Profit | -31.29 M | -23.54 M | -25.37 M | -46.89 M | -23.1 M |
| EPS in Rs | -0.41 | -0.31 | -0.33 | -0.62 | -0.3 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.64 M | 4.26 M | 1.82 M | 0.16 M |
| Operating Profit | -67.46 M | -76.96 M | -69.46 M | -22.37 M |
| Net Profit | -127.08 M | -251.39 M | -267.63 M | -16.89 M |
| EPS in Rs | -1.67 | -3.3 | -3.51 | -0.22 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 305.05 M | 350.07 M | 544.41 M | 22.42 M |
| Total Liabilities | 283.22 M | 252.24 M | 206.12 M | 15.19 M |
| Equity | 21.83 M | 92.16 M | 293.47 M | 7.23 M |
| Current Assets | 12.07 M | 16.95 M | 35.22 M | 4.13 M |
| Current Liabilities | 16.86 M | 19.88 M | 21.32 M | 1.66 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -50.59 M | -58.04 M | -46.21 M | -19.36 M |
| Investing CF | -0.58 M | -0.81 M | 55.06 M | -1.52 M |
| Financing CF | 46.65 M | 40.6 M | 20.32 M | 9.99 M |
| Free CF | -51.17 M | -58.85 M | -50.53 M | -20.88 M |
| Capex | -0.58 M | -0.81 M | -4.32 M | -1.52 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 134.56% | 1057.32% | — | — |
| Earnings Growth % | 6.07% | -1484.44% | — | — |
| Profit Margin % | -5898.36% | -14729.06% | -10758.6% | — |
| Operating Margin % | -1805.82% | -3823% | -14248.41% | — |
| Gross Margin % | 100% | 100% | 100% | — |
| EBITDA Margin % | -5669.52% | -17284.42% | -9726.11% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-06-01 | 1:0.2 |
| 2023-04-25 | 1:0.1 |